RAPT Therapeutics Statistics
Share Statistics
RAPT Therapeutics has 132.29M
shares outstanding. The number of shares has increased by 278.21%
in one year.
| Shares Outstanding | 132.29M |
| Shares Change (YoY) | 278.21% |
| Shares Change (QoQ) | 277.61% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 640 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 3.58M, so 2.71% of the outstanding
shares have been sold short.
| Short Interest | 3.58M |
| Short % of Shares Out | 2.71% |
| Short % of Float | 3.28% |
| Short Ratio (days to cover) | 4.73 |
Valuation Ratios
The PE ratio is -0.5 and the forward
PE ratio is -1.56.
RAPT Therapeutics's PEG ratio is
-0.11.
| PE Ratio | -0.5 |
| Forward PE | -1.56 |
| PS Ratio | 0 |
| Forward PS | 4.5 |
| PB Ratio | 0.34 |
| P/FCF Ratio | -0.77 |
| PEG Ratio | -0.11 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for RAPT Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.87,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.87 |
| Quick Ratio | 4.87 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.05 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,938,283.58 |
| Employee Count | 67 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -70.57% in the
last 52 weeks. The beta is -0.04, so RAPT Therapeutics's
price volatility has been lower than the market average.
| Beta | -0.04 |
| 52-Week Price Change | -70.57% |
| 50-Day Moving Average | 0.99 |
| 200-Day Moving Average | 1.45 |
| Relative Strength Index (RSI) | 66.53 |
| Average Volume (20 Days) | 815,607 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -136.1M |
| Net Income | -129.87M |
| EBITDA | -126.33M |
| EBIT | -129.87M |
| Earnings Per Share (EPS) | -3.19 |
Full Income StatementBalance Sheet
The company has 169.74M in cash and 4.49M in
debt, giving a net cash position of 165.24M.
| Cash & Cash Equivalents | 169.74M |
| Total Debt | 4.49M |
| Net Cash | 165.24M |
| Retained Earnings | -614.55M |
| Total Assets | 187.57M |
| Working Capital | 174.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -83.3M
and capital expenditures -122K, giving a free cash flow of -83.42M.
| Operating Cash Flow | -83.3M |
| Capital Expenditures | -122K |
| Free Cash Flow | -83.42M |
| FCF Per Share | -2.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
